Dystrophin pre-mRNA exon 44 splicing modulator

The "Dystrophin pre-mRNA exon 44 splicing modulator" refers to a molecular target within the *DMD* gene's precursor messenger RNA, specifically at the sequence corresponding to exon 44. This region is targeted by antisense oligonucleotides designed to alter normal RNA processing so that exon 44 is excluded ("skipped") during mRNA maturation. Skipping this specific exon can restore the correct translational reading frame for certain mutations that cause Duchenne muscular dystrophy, allowing cells to produce a shorter but still functional form of the essential muscle protein, dystrophin. This approach aims not for full cure but for conversion from severe Duchenne phenotype toward a milder Becker-like phenotype by enabling partial restoration of muscle function. Drugs such as NS‐089/NCNP‐02 and AOC 1044 are examples currently under investigation that act via this mechanism. The main therapeutic challenge lies in achieving efficient delivery and sufficient levels of targeted skipping without significant off-target effects or toxicity[1][2][3][8].

Other names

DMD exon 44 splicing modulatorExon 44 skipping target (DMD)Dystrophin exon 44 splice siteDMD pre-mRNA exon 44 splice modulator

Antisense oligonucleotide-mediated modulation of pre-mRNA splicing to induce skipping of exon 44, restoring the open reading frame and enabling production of functional or partially functional dystrophin protein[1][3][8].